Evidence map›Paper›PMID 30445924›Full record

ArticleBMC infectious diseases2018

Evaluation of Influenza A H1N1 infection and antiviral utilization in a tertiary care hospital.

Talita Rantin Belucci, Alexandre R Marra, Michael B Edmond, João Renato Rebello Pinho, Paula Kiyomi Onaga Yokota, Ana Carolina Cintra Nunes Mafra, Oscar Fernando Pavão Dos Santos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Talita Rantin BelucciHospital Israelita Albert Einstein, São Paulo, Brazil. talita.belucci@hotmail.com.ORCID http://orcid.org/0000-0001-9435-6267
Alexandre R MarraDivision of Medical Practice, Hospital Israelita Albert Einstein, Avenida Albert Einstein, 627 - bloco A1, 1° andar, Morumbi, São Paulo, 05651-901, Brazil.
Michael B EdmondOffice of Clinical Quality, Safety and Performance Improvement, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
João Renato Rebello PinhoClinical Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Paula Kiyomi Onaga YokotaDivision of Medical Practice, Hospital Israelita Albert Einstein, Avenida Albert Einstein, 627 - bloco A1, 1° andar, Morumbi, São Paulo, 05651-901, Brazil.
Ana Carolina Cintra Nunes MafraStatistics Department, Instituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Oscar Fernando Pavão Dos SantosDivision of Medical Practice, Hospital Israelita Albert Einstein, Avenida Albert Einstein, 627 - bloco A1, 1° andar, Morumbi, São Paulo, 05651-901, Brazil.
Hospital Israelita Albert Einstein · BRUniversity of Iowa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfluenza A H1N1 infections carry a significant mortality risk. This study describes inpatients with suspected and confirmed Influenza A H1N1 infection who were prescribed oseltamivir, the risk factors associated with infection, the association between infection and mortality, and the factors associated with in-hospital mortality in infected patients.

methodsThis study was a matched case-control study of hospitalized patients who underwent real-time polymerase chain reaction testing for Influenza A H1N1 and were treated with oseltamivir from 2009 to 2015 in a tertiary care hospital. Cases (patients with positive Influenza A H1N1 testing) were matched 1:1 to controls (patients with negative test results).

resultsA total of 1405 inpatients who underwent PCR testing and received treatment with oseltamivir were identified in our study and 157 patients confirmed Influenza A H1N1. Almost one third of patients with Influenza A H1N1 were diagnosed in the pandemic period. There was no difference in mortality between cases and controls. Immunocompromised status, requirement of vasoactive drugs, mechanical ventilation, acute hemodialysis, albumin administration, surgical procedures and thoracic procedures and length of stay were associated with increased risk of death in Influenza A H1N1 infected patients.

conclusionsWe found no increased risk of mortality for patients with proven Influenza A H1N1 when compared to similar patients without confirmed Influenza.

Indexed as

Influenza A Virus, H1N1 SubtypeAdultAgedAged, 80 and overAntiviral AgentsBrazilCase-Control StudiesDrug Utilization ReviewFemaleHospitalizationHospital MortalityHumansInfluenza, HumanMaleMiddle AgedOseltamivirAntiviral AgentsOseltamivirHospitalized patientsInfluenza a H1N1Oseltamivir

Identifiers

PMID30445924
PMCPMC6240327
OpenAlexW2900615744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.